Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640951 · ClinicalTrials.gov registry record · Phase 3
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
A Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 20
- Study locations
NCT01640951 is a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 675 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT01640951, a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 20
- Study locations
Study Summary
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects who completed the full study treatment period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to participate in this extension study. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab was used.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AIN457 150 mg
- DRUG AIN457 300 mg
Study Locations (20)
Florida
- Novartis Investigative Site - Jacksonville
- Novartis Investigative Site - Jacksonville
- Novartis Investigative Site - Miami
- Novartis Investigative Site - South Miami
- Novartis Investigative Site - West Palm Beach
California
- Novartis Investigative Site - Fresno
- Novartis Investigative Site - Pasadena
- Novartis Investigative Site - San Francisco
Illinois
- Novartis Investigative Site - Champaign
- Novartis Investigative Site - Skokie
Nevada
- Novartis Investigative Site - Henderson
- Novartis Investigative Site - Las Vegas
Georgia
- Novartis Investigative Site - Atlanta
Indiana
- Novartis Investigative Site - Indianapolis
Kansas
- Novartis Investigative Site - Overland Park
Massachusetts
- Novartis Investigative Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2012-09-16 |
| Est. Completion | 2017-05-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640951
The ClinicalTrials.gov registry entry for NCT01640951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Chronic Plaque-Type Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01640951 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01640951 about?
NCT01640951 is a clinical study titled "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis". CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of...
What is the current status of trial NCT01640951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2012-09-16. Estimated completion is 2017-05-04.
What conditions does trial NCT01640951 study?
This clinical trial studies the following conditions: Moderate to Severe Chronic Plaque-Type Psoriasis.
What interventions are being tested in trial NCT01640951?
The interventions under investigation include: Placebo (DRUG), AIN457 150 mg (DRUG), AIN457 300 mg (DRUG).
Who is sponsoring clinical trial NCT01640951?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01640951 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Chronic Plaque-Type Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.